5-FU-based Chemotherapy in Pancreatic Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival Abstract #852

Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.
Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients with PNENs.
Materials and methods: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013. Dihydropyrimidin-Dehydrogenase (DPD) and Thymidylat-Synthase (TS) expression was correlated with treatment response in 19 patients who had available tumor tissue and response data. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
Keywords: 5-fluorouracil, DPD, PNEN

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1009 Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival
Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
Authors: Krug S, Boch M, Rinke A, Müller D, ...
#2836 Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience
Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Anna Malczewska
#2852 Diagnostic Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) in the Evaluation of Pancreatic Neuroendocrine Neoplasms (PNEN) Grading
Introduction: Prognosis of pNENs depends on staging and grading, based on the cyto-histological Ki67 labelling; EUS-FNA is considered the gold standard technique to obtain it in pre-therapeutic setting
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Matteo Tacelli
#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro
Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Sebastian Krug